Are pharma stocks ready for a rally? Here’s what Devang Mehta has to say
“We are into MNC pharma companies like Abbot Laboratories. After the correction, we have also started to buy into Dr Lal Path Labs, a company with 35-40% ROEs, a company which has a larger market share of around Rs 800 revenues per patient. These are some metrics which we like. Apart from it, we also like the CRAM space, where Syngene has been one of the top picks in the last two, three years.”